secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001437749-25-016997
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart gets BARDA approval to start dosing 10,000 participants in Phase 2b COVID vaccine trial
--------------------------------------------------------------------------------

- BARDA approved initiation of dosing in 10,000-participant Phase 2b trial of oral COVID-19 vaccine.
- First patient expected to be dosed in Q2 2025, per CEO Steven Lo.
- Trial is double-blind, randomized, comparator-controlled vs approved mRNA COVID-19 vaccine.
- Funding under Project NextGen via RRPV Consortium valued at up to $460.7M.
- Funding from HHS/ASPR/BARDA under Other Transaction 75A50123D00005.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925016997/0001437749-25-016997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925016997/vxrt20250515_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer